Results 61 to 70 of about 696,549 (260)

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves, Arcaro, Asou, Bouscary, Bouscary, Bouscary, Bowles, Carroll, Carroll, DiPersio, Druker, Esmaeili-Mahani, Finan, Gandhi, Giese, Gilliland, Hirsch, Johnson, Jordan, Kahl, Khwaja, Khwaja, Ko, Konopleva, MacEwan, MacEwan, Niitsu, Pettitt, Pocock, Preudhomme, Recher, Ronnstrand, Rushworth, Solary, Ulrich, Wei, Wymann, Wymann   +37 more
core   +1 more source

Uncommon CD markers in acute myeloid leukemia

Bangabandhu Sheikh Mujib Medical University Journal, 2018
This study was done to assess the unusual CD expression in 100 cases of acute myeloid leukemia from October 2016 to April 2018. The age limit was from 3 to 50 years.
Azad Abul Kalam, Md. Rafiquzzaman Khan, A. B. M. Hassan Habib, Masuda Begum   +3 more
doaj   +1 more source

Troxacitabine in acute leukemia

Hematology, 2007
Troxacitabine (Troxatyl; BCH-4556; (-)-2'-deoxy-3'-oxacytadine) is the first synthetic l-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity. It was obtained by exchanging the sulphur endocyclic atom with oxygen in the structure of lamivudine, following the discovery that this agent had cytotoxic, as well as anti-viral activity.
Francis J. Giles, Ronan T. Swords
openaire   +3 more sources

Hierarchy in Gene Expression is Predictive for Adult Acute Myeloid Leukemia

, 2015
Cancer progresses with a change in the structure of the gene network in normal cells. We define a measure of organizational hierarchy in gene networks of affected cells in adult acute myeloid leukemia (AML) patients.
Deem, Michael W., Tripathi, Shubham
core   +1 more source

Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia [PDF]

, 2013
Key Points First report demonstrating in vivo elimination of multiple LIC populations from childhood ALL cases using animal models. In vivo models of leukemia are essential for drug evaluation studies.
Blair, Allison, Cox, Charlotte V, Diamanti, Paraskevi, Moppett, John P   +3 more
core   +1 more source

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. [PDF]

, 2019
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival ...
Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Alousi, Amin M., Arora, Mukta, Askar, Medhat, Auletta, Jeffery J., Bhatt, Vijaya, Bredeson, Christopher, Chhabra, Saurabh, Couriel, Daniel R., Diaz, Miguel Angel, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Gergis, Usama, Hematti, Peiman, Hemmer, Michael T., Hildebrandt, Gerhard C., Holtan, Shernan G, Inamoto, Yoshihiro, Khandelwal, Pooja, Kitko, Carrie, MacMillan, Margaret L., Majhail, Navneet, Marks, David I., Mehta, Parinda, Mehta, Rohtesh S., Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Pidala, Joseph, Prestidge, Tim, Qayed, Muna, Rangarajan, Hemalatha, Ringden, Olle, Saad, Ayman, Savani, Bipin N., Schultz, Kirk R., Seo, Sachiko, Shah, Ami, Shah, Niketa, Solh, Melhem, Spellman, Stephen R., Spitzer, Thomas, Szer, Jeffrey, Teshima, Takanori, Verdonck, Leo F, Wagner, John, Wang, Tao, Weisdorf, Daniel J., Williams, Kirsten M., Wirk, Baldeep, Yared, Jean A.   +53 more
core   +2 more sources

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Haematologica, 2019
The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the in vitro impact ...
Evgeniya Angelova, Charlene Audette, Yelena Kovtun, Naval Daver, Sa A. Wang, Sherry Pierce, Sergej N. Konoplev, Haitham Khogeer, Jeffrey L. Jorgensen, Marina Konopleva, Patrick A. Zweidler-McKay, L. Jeffrey Medeiros, Hagop M. Kantarjian, Elias J. Jabbour, Joseph D. Khoury   +14 more
doaj   +1 more source

Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia [PDF]

, 2000
At diagnosis, clonal gene rearrangement probes {[}retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3 ...
Braun, S., Duell, T., Gerhartz, Helmut Heinrich, Mittermueller, J., Schmetzer, Helga Maria, Wiesner, D.   +5 more
core   +1 more source

P1688: LIVING WITH ACUTE LEUKEMIA: A GLOBAL SURVEY OF PATIENTS AND CARERS EXPERIENCE

HemaSphere, 2023
Samantha Nier, Zack Pemberton-Whiteley, Jan Geissler, Anne-Pierre Pickaert, Sophie Wintrich, Cheryl Petruk, Esther Nathalie Oliva, Tatyana Ionova, Sam Salek   +8 more
doaj   +1 more source

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Haematologica, 2019
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou, Jessie Yiying Quah, Yvonne Ng, Jing-Yuan Chooi, Sabrina Hui-Min Toh, Baohong Lin, Tuan Zea Tan, Hiroki Hosoi, Motomi Osato, Qihui Seet, A.G. Lisa Ooi, Bertil Lindmark, Mark McHale, Wee-Joo Chng   +13 more
doaj   +1 more source